Is International Reference Pricing Still Relevant?
International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.
You may also be interested in...
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.